Tweet
Hi, Does anyone know the sequencing error rates in Illumina platform?
-
-
The Illumina specificity for the v4 kit (75 PE) is of 1.33 % forward and almost 1.7 reverse, for a Qphred of 30 -
If my data is 75bp not strand, it means that it close to 1bp error per read?Originally posted by francois.sabot View PostComment
-
Yes, theoretically. But it seems to be better to consider it somehow a little higher (around 2% max). Do not forget that you may also have SNP/InDel between your ref and your data, thus explaining some 'errors' you might seeComment
-
That's true; Thanks~Comment
-
The are much more likely to occur at the 3' end of the read, and, a proportion of the reads have much more than one error, so lots of reads will be error free.Originally posted by sixguns View Post
HOWEVER I think the Illumina error rate may be misleading us. I believe they only count MAPPABLE reads to their PHIX74 CONTROL. Now, a read which has lots of errors will NOT MAP, hence will not count toward the error rate! Simply by tweaking their mappability thresholds, they can choose any error rate they want to match a reasonable yield...Comment
-
Yes but how can you calculate the 'true' errors rate, meaning the level of misreading, the level of chimeria, etc... For that you must know perfectly your DNA you are sequencing, and you cannot, due to continual modification of it... However, you can estimate it based on the common sequences between reference and tested sequences, and in calculating the false of non-SNP mismatches /indels.Comment
-
Francois, is there a paper/document describing in more details the suggestions you just gave above. I have DNA which we prepared by doing PCR on a normal individual,confirmed size by CE and also are planning to do Sanger sequencing.Comment
-
In fact those specs came from my classical provider (Integragen, France), from their own experience... No paper associated with so. Sorry :sOriginally posted by cdry7ue View PostComment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment